目的 通过快速评价为医疗机构遴选原研及国家集采的选择性5-羟色胺再摄取抑制剂（SSRIs）类抗抑郁药提供科学高效的参考依据，明确其临床应用价值，进而初步探究将原研药品及集采药品分别评价与二者整合评价之间存在的差异性。方法 应用《中国医疗机构药品评价与遴选快速指南（第二版）》进行初步的评价实践，通过药学特性、有效性、安全性、经济性和其他等5个方面分别对原研SSRIs、国家集采SSRIs以及原研合并集采的SSRIs整体进行逐项评价。结果 评价结果表明可通过快速指南分别对SSRIs的原研药品及集采药品进行遴选与评价，从而排序出临床应用首选的先后名次，而将原研药品及集采药品整合在一起共同评价并不适用。结论 可应用《中国医疗机构药品评价与遴选快速指南（第二版）》对相关药品进行遴选与评价，以便促进临床合理用药。但是仅限于同一药品采购分类，即此快速评价并不适用于同一通用名称的原研药品、集采药品同时评价。

Objective The rapid evaluation provides scientific and efficient reference basis for medical institutions to select the innovator drugs and national centralized purchase drugs of SSRIs antidepressants, clarify their clinical application value, and then preliminatively explore the differences between the separate evaluation of the innovator drugs, National centralized purchase drugs and the integrated evaluation of the two. Methods The Rapid Guide for the Evaluation and Selection of Drugs in Chinese Medical Institutions (Second Edition) was applied to conduct preliminary evaluation practice, and the innovator drugs of SSRIs, centralized purchase drugs of SSRIs and the innovator drugs combined with centralized purchase drugs of SSRIs were evaluated one by one through five aspects, such as pharmaceutical characteristics, effectiveness, safety, economy and other aspects. Results The evaluation results showed that the rapid guide could be used to select and evaluate the innovator drugs and the centralized purchase drugs of SSRIs respectively, so as to sort out the priority of clinical application, while the innovator drugs combined with centralized purchase drugs of SSRIs were not suitable for this evaluation. Conclusion This article shows that the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition) can be applied to select and evaluate related drugs in order to promote rational clinical use of drugs. However, this rapid evaluation is limited to the same drug procurement classification, that is, this rapid evaluation does not apply to the original drug of the same generic name, the collective drug evaluation at the same time.

R749